To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

How to transfigure the Wikipedia

Would you like Wikipedia to always look as professional and up-to-date? We have created a browser extension. It will enhance any encyclopedic page you visit with the magic of the WIKI 2 technology.

Try it — you can delete it anytime.

Install in 5 seconds
4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
Great Wikipedia has got greater.
.
Leo
Newton
Brights
Milds

CDR132L

From Wikipedia, the free encyclopedia

CDR132L is an antisense RNA therapy that inhibits MiR-132. It is developed by Cardior Pharmaceuticals to treat heart failure.[1][2][3]

References

  1. ^ Batkai, Sandor; Genschel, Celina; Viereck, Janika; Rump, Steffen; Bär, Christian; Borchert, Tobias; Traxler, Denise; Riesenhuber, Martin; Spannbauer, Andreas; Lukovic, Dominika; Zlabinger, Katrin; Hašimbegović, Ena; Winkler, Johannes; Garamvölgyi, Rita; Neitzel, Sonja; Gyöngyösi, Mariann; Thum, Thomas (7 January 2021). "CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure". European Heart Journal. 42 (2): 192–201. doi:10.1093/eurheartj/ehaa791. PMC 7813625.
  2. ^ Taubel, Jorg; Hauke, Wilfried; Rump, Steffen; Viereck, Janika; Batkai, Sandor; Jenny, Poetzsch; Laura, Rode; Weigt, Henning; Genschel, Celina; Lorch, Ulrike; Theek, Carmen; Levin, Arthur A; Bauersachs, Johann B; Solomon, Scott D; Thum, Thomas (3 September 2021). "Abstract 114: Safety And Efficacy Of CDR132L, A Novel Antisense Therapeutic Which Targets MicroRNA-132 In Heart Failure Patients". Circulation Research. 129 (Suppl_1). doi:10.1161/res.129.suppl_1.114.
  3. ^ Täubel, Jörg; Hauke, Wilfried; Rump, Steffen; Viereck, Janika; Batkai, Sandor; Poetzsch, Jenny; Rode, Laura; Weigt, Henning; Genschel, Celina; Lorch, Ulrike; Theek, Carmen; Levin, Arthur A; Bauersachs, Johann; Solomon, Scott D; Thum, Thomas (11 November 2020). "Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study". European Heart Journal. 42 (2): 178–188. doi:10.1093/eurheartj/ehaa898. ISSN 0195-668X. PMC 7954267.
This page was last edited on 4 January 2024, at 17:23
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.
Contact WIKI 2
Introduction
Terms of Service
Privacy Policy